SEC Form 4 · accession 0001209191-15-046667

SURMODICS INC · SRDX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — SVP, Gen Counsel & Secretary

Period of report

May 21, 2015

Accepted (ET)

May 26, 2015 · 4:19 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000924717

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	May 21, 2015	M	7,748	$9.25	A	33,435	D
Common Stock	May 21, 2015	M	5,367	$12.40	A	38,802	D
Common Stock	May 21, 2015	F	7,984	$25.94	D	30,818	D
Common Stock^F3	May 22, 2015	S	7,293	$25.2494	D	23,525	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F4	$9.25	May 21, 2015	M	7,748	D	—	Nov 30, 2017	Common Stock	7,748	0	D
Employee Stock Option (right to buy)^F5	$12.40	May 21, 2015	M	5,367	D	—	Nov 30, 2018	Common Stock	5,367	5,367	D

F1The reporting person makes a payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3.
F2Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2015.
F3Reflects the weighted average price of 7,293 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on May 22, 2015 with sale prices ranging from $24.92 to $25.81 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4Fully vested.
F5The award vests in four equal installments of each of the first four anniversaries of the November 30, 2011 grant date.